525 related articles for article (PubMed ID: 22365040)
1. Impact of high glucose and transforming growth factor-β on bioenergetic profiles in podocytes.
Stieger N; Worthmann K; Teng B; Engeli S; Das AM; Haller H; Schiffer M
Metabolism; 2012 Aug; 61(8):1073-86. PubMed ID: 22365040
[TBL] [Abstract][Full Text] [Related]
2. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy.
Susztak K; Raff AC; Schiffer M; Böttinger EP
Diabetes; 2006 Jan; 55(1):225-33. PubMed ID: 16380497
[TBL] [Abstract][Full Text] [Related]
3. Parathyroid hormone-related protein induces hypertrophy in podocytes via TGF-beta(1) and p27(Kip1): implications for diabetic nephropathy.
Romero M; Ortega A; Izquierdo A; López-Luna P; Bosch RJ
Nephrol Dial Transplant; 2010 Aug; 25(8):2447-57. PubMed ID: 20200004
[TBL] [Abstract][Full Text] [Related]
4. The role of metabolic and haemodynamic factors in podocyte injury in diabetes.
Stieger N; Worthmann K; Schiffer M
Diabetes Metab Res Rev; 2011 Mar; 27(3):207-15. PubMed ID: 21309047
[TBL] [Abstract][Full Text] [Related]
5. Galectin-9 inhibits glomerular hypertrophy in db/db diabetic mice via cell-cycle-dependent mechanisms.
Baba M; Wada J; Eguchi J; Hashimoto I; Okada T; Yasuhara A; Shikata K; Kanwar YS; Makino H
J Am Soc Nephrol; 2005 Nov; 16(11):3222-34. PubMed ID: 16177004
[TBL] [Abstract][Full Text] [Related]
6. Bone morphogenetic protein-7 delays podocyte injury due to high glucose.
De Petris L; Hruska KA; Chiechio S; Liapis H
Nephrol Dial Transplant; 2007 Dec; 22(12):3442-50. PubMed ID: 17686813
[TBL] [Abstract][Full Text] [Related]
7. Thioredoxin-Interacting Protein Deficiency Protects against Diabetic Nephropathy.
Shah A; Xia L; Masson EA; Gui C; Momen A; Shikatani EA; Husain M; Quaggin S; John R; Fantus IG
J Am Soc Nephrol; 2015 Dec; 26(12):2963-77. PubMed ID: 25855771
[TBL] [Abstract][Full Text] [Related]
8. BMP7 is a podocyte survival factor and rescues podocytes from diabetic injury.
Mitu GM; Wang S; Hirschberg R
Am J Physiol Renal Physiol; 2007 Nov; 293(5):F1641-8. PubMed ID: 17804487
[TBL] [Abstract][Full Text] [Related]
9. Suppressions of chronic glomerular injuries and TGF-beta 1 production by HGF in attenuation of murine diabetic nephropathy.
Mizuno S; Nakamura T
Am J Physiol Renal Physiol; 2004 Jan; 286(1):F134-43. PubMed ID: 14519594
[TBL] [Abstract][Full Text] [Related]
10. Swiprosin-1 Promotes Mitochondria-Dependent Apoptosis of Glomerular Podocytes via P38 MAPK Pathway in Early-Stage Diabetic Nephropathy.
Wang RM; Wang ZB; Wang Y; Liu WY; Li Y; Tong LC; Zhang S; Su DF; Cao YB; Li L; Zhang LC
Cell Physiol Biochem; 2018; 45(3):899-916. PubMed ID: 29421811
[TBL] [Abstract][Full Text] [Related]
11. Advanced glycation end-products induce cell cycle arrest and hypertrophy in podocytes.
Rüster C; Bondeva T; Franke S; Förster M; Wolf G
Nephrol Dial Transplant; 2008 Jul; 23(7):2179-91. PubMed ID: 18344241
[TBL] [Abstract][Full Text] [Related]
12. Mechanical stretch and prostaglandin E2 modulate critical signaling pathways in mouse podocytes.
Faour WH; Thibodeau JF; Kennedy CR
Cell Signal; 2010 Aug; 22(8):1222-30. PubMed ID: 20362052
[TBL] [Abstract][Full Text] [Related]
13. Podocytes and the struggle against glucose toxicity: new targets for treatment?
Gnudi L
Metabolism; 2012 Aug; 61(8):1051-4. PubMed ID: 22386941
[No Abstract] [Full Text] [Related]
14. Islet transplantation restores the damage of glomerulus filtration membrane in a rat model of streptozotocin-induced diabetic nephropathy.
Ziqiang X; Yunqiang H; Hongxing F; Jinjun W; Yong C
J Pak Med Assoc; 2016 Mar; 66(3):296-301. PubMed ID: 26968280
[TBL] [Abstract][Full Text] [Related]
15. Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production.
Toyonaga J; Tsuruya K; Ikeda H; Noguchi H; Yotsueda H; Fujisaki K; Hirakawa M; Taniguchi M; Masutani K; Iida M
Nephrol Dial Transplant; 2011 Aug; 26(8):2475-84. PubMed ID: 21220752
[TBL] [Abstract][Full Text] [Related]
16. Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms.
Okada T; Wada J; Hida K; Eguchi J; Hashimoto I; Baba M; Yasuhara A; Shikata K; Makino H
Diabetes; 2006 Jun; 55(6):1666-77. PubMed ID: 16731829
[TBL] [Abstract][Full Text] [Related]
17. Celecoxib modifies glomerular basement membrane, mesangium and podocytes in OVE26 mice, but ibuprofen is more detrimental.
Nasrallah R; Robertson SJ; Karsh J; Hébert RL
Clin Sci (Lond); 2013 Jun; 124(11):685-94. PubMed ID: 23305077
[TBL] [Abstract][Full Text] [Related]
18. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis.
Isermann B; Vinnikov IA; Madhusudhan T; Herzog S; Kashif M; Blautzik J; Corat MA; Zeier M; Blessing E; Oh J; Gerlitz B; Berg DT; Grinnell BW; Chavakis T; Esmon CT; Weiler H; Bierhaus A; Nawroth PP
Nat Med; 2007 Nov; 13(11):1349-58. PubMed ID: 17982464
[TBL] [Abstract][Full Text] [Related]
19. Antioxidants ameliorate the expression of vascular endothelial growth factor mediated by protein kinase C in diabetic podocytes.
Lee EY; Chung CH; Kim JH; Joung HJ; Hong SY
Nephrol Dial Transplant; 2006 Jun; 21(6):1496-503. PubMed ID: 16484238
[TBL] [Abstract][Full Text] [Related]
20. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy.
Ziyadeh FN; Wolf G
Curr Diabetes Rev; 2008 Feb; 4(1):39-45. PubMed ID: 18220694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
